DEPRESSION THERAPEUTICS MARKET ANALYSIS

Depression Therapeutics Market, By Drug Type [Antidepressants (Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Serotonin Modulators, Tricyclic & Tetracyclic Antidepressants, and Atypical Antidepressants), Antipsychotics, Others], By Indication (Major Depressive Disorder (MDD), Bipolar Disorder, Dysthymic Disorder, Postpartum Depression, Seasonal Affective Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Sep 2023
Code : CMI1307
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Depression Therapeutics Market - Key Players

Major players operating in the global depression therapeutics market include Johnson & Johnson, GlaxoSmithKline plc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., Eli Lilly and Company, Sanofi S.A., Pfizer, Inc., Allergan plc., H. Lundbeck A/S, Alkermes, Allergan, Novartis AG, Biogen, Sage Therapeutics, Inc., and AbbVie Inc.

Companies covered:

Johnson & Johnson, GlaxoSmithKline plc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., Eli Lilly and Company, Sanofi S.A., Pfizer, Inc., Allergan plc., H. Lundbeck A/S, Alkermes, Allergan, Novartis AG, Biogen, Sage Therapeutics, Inc., and AbbVie Inc.

Key players